Organon
Organon

Organon

Pharmaceuticals
WebsiteInvestor RelationsSEC
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women’s health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.

$3.6B

Market Cap • 9/29/2026

2020

(6 years)

Founded

2021

(5 years ago)

IPO

NYSE

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

3,6

P/S

0,6

P/EBITDA

3,1

P/OCF

4,9

P/FCF

6,4

P/E

17,8

BVPS

3,8

EPS

0,8

Market Cap

Market Cap

3,6B

EV

11B

EV/Revenue

1,8

EV/EBITDA

9,4

EV/EBIT

13,4

Payout

Dividend Per Share

0,1

Dividend Yield

0,5%

Buyback Yield

0%

Total Yield

0,5%

Dividend Yield 5Y

4,5%

Payout

8,6%

Retained Earnings

1,4B

Profitability

Gross Margin

52,7%

EBITDA Margin

19,2%

EBIT Margin

13,4%

Net Margin

3,4%

D&A/EBITDA

0%

R&D/Revenue

5,9%

Capex/Revenue

2,8%

Capex/D&A

48%

Capex/OCF

23,1%

SBC/OCF

10,2%

% PPE

9,7%

% Goodwill

31,5%

ROE

24%

ROIC

3,6%

Growth

CAGR Revenue 5Y

-0,6%

CAGR Op. Income 5Y

-17,8%

CAGR Net Income 5Y

-34,7%

CAGR EPS 5Y

-35,5%

CAGR OCF 5Y

-23,2%

Leverage

N.D./EBITDA

6,3

Debt/Equity

0%

Current Ratio

2

Quick Ratio

1

Interest Coverage

176,1%

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium